These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24243035)

  • 21. Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies.
    Santos JI; Teixeira AL; Dias F; Maurício J; Lobo F; Morais A; Medeiros R
    Tumour Biol; 2014 Jul; 35(7):7105-13. PubMed ID: 24760272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer.
    Barron N; Keenan J; Gammell P; Martinez VG; Freeman A; Masters JR; Clynes M
    Prostate; 2012 Aug; 72(11):1193-9. PubMed ID: 22161972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tpl2 induces castration resistant prostate cancer progression and metastasis.
    Lee HW; Cho HJ; Lee SJ; Song HJ; Cho HJ; Park MC; Seol HJ; Lee JI; Kim S; Lee HM; Choi HY; Nam DH; Joo KM
    Int J Cancer; 2015 May; 136(9):2065-77. PubMed ID: 25274482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GPX2 overexpression is involved in cell proliferation and prognosis of castration-resistant prostate cancer.
    Naiki T; Naiki-Ito A; Asamoto M; Kawai N; Tozawa K; Etani T; Sato S; Suzuki S; Shirai T; Kohri K; Takahashi S
    Carcinogenesis; 2014 Sep; 35(9):1962-7. PubMed ID: 24562575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
    Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
    Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pirin: a potential novel therapeutic target for castration-resistant prostate cancer regulated by miR-455-5p.
    Arai T; Kojima S; Yamada Y; Sugawara S; Kato M; Yamazaki K; Naya Y; Ichikawa T; Seki N
    Mol Oncol; 2019 Feb; 13(2):322-337. PubMed ID: 30444038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Microdissecting the role of microRNAs in the pathogenesis of prostate cancer.
    Ayub SG; Kaul D; Ayub T
    Cancer Genet; 2015 Jun; 208(6):289-302. PubMed ID: 26004033
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Non-coding RNAs in castration-resistant prostate cancer].
    Xie GP; Jiang R
    Zhonghua Nan Ke Xue; 2015 Nov; 21(11):1014-9. PubMed ID: 26738330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2.
    Ma S; Chan YP; Kwan PS; Lee TK; Yan M; Tang KH; Ling MT; Vielkind JR; Guan XY; Chan KW
    Cancer Res; 2011 Jan; 71(2):583-92. PubMed ID: 21224345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
    McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
    Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.
    Liu C; Wang C; Wang K; Liu L; Shen Q; Yan K; Sun X; Chen J; Liu J; Ren H; Liu H; Xu Z; Hu S; Xu D; Fan Y
    J Natl Cancer Inst; 2013 Nov; 105(22):1719-28. PubMed ID: 24174655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. microRNA-330 inhibits cell motility by downregulating Sp1 in prostate cancer cells.
    Mao Y; Chen H; Lin Y; Xu X; Hu Z; Zhu Y; Wu J; Xu X; Zheng X; Xie L
    Oncol Rep; 2013 Jul; 30(1):327-33. PubMed ID: 23670210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-23b and microRNA-27b plus flutamide treatment enhances apoptosis rate and decreases CCNG1 expression in a castration-resistant prostate cancer cell line.
    Pimenta RC; Viana NI; Amaral GQ; Park R; Morais DR; Pontes J; Guimaraes VR; Camargo JA; Leite KR; Nahas WC; Srougi M; Reis ST
    Tumour Biol; 2018 Nov; 40(11):1010428318803011. PubMed ID: 30400755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer.
    Goto Y; Kurozumi A; Arai T; Nohata N; Kojima S; Okato A; Kato M; Yamazaki K; Ishida Y; Naya Y; Ichikawa T; Seki N
    Br J Cancer; 2017 Jul; 117(3):409-420. PubMed ID: 28641312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. miR-152 controls migration and invasive potential by targeting TGFα in prostate cancer cell lines.
    Zhu C; Li J; Ding Q; Cheng G; Zhou H; Tao L; Cai H; Li P; Cao Q; Ju X; Meng X; Qin C; Hua L; Shao P; Yin C
    Prostate; 2013 Jul; 73(10):1082-9. PubMed ID: 23460133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.
    Patnaik SK; Kannisto E; Knudsen S; Yendamuri S
    Cancer Res; 2010 Jan; 70(1):36-45. PubMed ID: 20028859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network.
    Zhu J; Wang S; Zhang W; Qiu J; Shan Y; Yang D; Shen B
    Oncotarget; 2015 Dec; 6(41):43819-30. PubMed ID: 26540468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Downregulation of miR-195 promotes prostate cancer progression by targeting HMGA1.
    Zhang X; Tao T; Liu C; Guan H; Huang Y; Xu B; Chen M
    Oncol Rep; 2016 Jul; 36(1):376-82. PubMed ID: 27175617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer.
    Ylipää A; Kivinummi K; Kohvakka A; Annala M; Latonen L; Scaravilli M; Kartasalo K; Leppänen SP; Karakurt S; Seppälä J; Yli-Harja O; Tammela TL; Zhang W; Visakorpi T; Nykter M
    Cancer Res; 2015 Oct; 75(19):4026-31. PubMed ID: 26282172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miRNA-30a functions as a tumor suppressor by downregulating cyclin E2 expression in castration-resistant prostate cancer.
    Zhang L; Zhang XW; Liu CH; Lu K; Huang YQ; Wang YD; Xing L; Zhang LJ; Liu N; Jiang H; Sun C; Yang Y; Chen SQ; Chen M; Xu B
    Mol Med Rep; 2016 Sep; 14(3):2077-84. PubMed ID: 27431942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.